559 件 ・ 関連度順
概要と使いどころ
Recommends initiating hydrocortisone replacement at a total starting dose of 8 mg/m2 body surface area per day, given in three or four divided doses, for children with confirmed primary adrenal insufficiency (PAI). Use when starting glucocorticoid therapy in pediatric PAI patients, adjusting the dose according to individual clinical response, growth, and need for stress coverage.
日本語の概要は準備中です。原文の説明を表示しています。
The Endocrine Society recommends a standard-dose corticotropin (ACTH) stimulation test to confirm primary adrenal insufficiency when clinical suspicion arises from symptoms such as hypotension, hyponatremia, hyperkalemia, or unexplained fatigue. Dosing is weight/age based: 250 µg for adults and children ≥2 years, 15 µg/kg for infants, and 125 µg for children <2 years.
日本語の概要は準備中です。原文の説明を表示しています。
Recommends diagnostic testing to exclude primary adrenal insufficiency (PAI) in acutely ill patients presenting with otherwise unexplained volume depletion, hypotension, hyponatremia, hyperkalemia, fever, abdominal pain, hyperpigmentation, or hypoglycemia (especially in children). Use when clinical suspicion arises from these suggestive signs or symptoms suggestive of PAI.
日本語の概要は準備中です。原文の説明を表示しています。
Recommends withdrawing interfering medications and repeating aldosterone-to-renin ratio screening when initial screen is negative but clinical suspicion remains due to hypokalemia or medication interference. Trigger phrases include "initial screen negative", "hypokalemia", "resistant hypertension", and use of MRAs, ACE inhibitors, ARBs, beta-blockers, clonidine, or alpha-methyldopa.
日本語の概要は準備中です。原文の説明を表示しています。
Interprets the postural stimulation test to detect angiotensin II‑unresponsive aldosterone‑producing adenoma (APA) or familial hyperaldosteronism type I (FH‑I) when aldosterone fails to rise with upright posture. Triggered by clinical cues such as “postural stimulation test shows no aldosterone increase”, “suspected APA with non‑responsive aldosterone”, or “evaluating FH‑I in young patients with early‑onset hypertension and hypokalemia”.
日本語の概要は準備中です。原文の説明を表示しています。
Guides comorbidity-stratified selection of initial and further glucose-lowering medicines for adults with type 2 diabetes using the NICE NG28 (2026) framework, covering six clinical profiles: no relevant comorbidity, heart failure, atherosclerotic cardiovascular disease, early onset, obesity, chronic kidney disease, and frailty.
日本語の概要は準備中です。原文の説明を表示しています。
Work a primary-prevention patient through the 2026 ACC/AHA multisociety dyslipidaemia guideline CPR framework — Calculate (10-year and 30-year PREVENT-ASCVD), Classify (low / borderline / intermediate / high), Personalize (demographic, clinical, biomarker, and reproductive risk enhancers), and Reclassify (coronary artery calcium scoring where appropriate). Use when a clinician asks how to assess ASCVD risk for primary prevention, who needs a statin, borderline risk patient what to do, intermediate risk should I start a statin, risk enhancers to look for, premature family history of ASCVD how does it change risk, pregnancy-related risk factors, PCOS and cardiovascular risk. Grounded in the 2026 ACC/AHA multisociety dyslipidaemia guideline.
日本語の概要は準備中です。原文の説明を表示しています。
In patients with normal preoperative adrenal function, suggests an individualized clinical approach for postoperative glucocorticoid administration until HPA axis evaluation can be performed. Triggers include managing postoperative patient with normal preoperative adrenal function needing glucocorticoid management.
日本語の概要は準備中です。原文の説明を表示しています。
Expert-level tissue engineering covering scaffold design, cell culture, bioreactors, stem cells, vascularization, and clinical translation of engineered tissues.
日本語の概要は準備中です。原文の説明を表示しています。
Expert-level biomedical imaging covering X-ray, CT, MRI, ultrasound, nuclear medicine, optical imaging, and image processing for clinical and research applications.
日本語の概要は準備中です。原文の説明を表示しています。
Clinical copy-editor that reviews text for communication issues. Use when user says review for prose or improve the prose
日本語の概要は準備中です。原文の説明を表示しています。
Retrieves scientific papers from PubMed and creates plain-language research summaries. Use when users ask about medical research, scientific studies, clinical trials, disease treatments, or want to understand recent scientific literature on any biomedical topic.
日本語の概要は準備中です。原文の説明を表示しています。
中国药品权威数据库查询 — NMPA(国家药监局) + CDE(药品审评中心) + DrugBank(英文名/ATC) + PubChem(化学结构) 多源融合,提供(通用名 ↔ 商品名 ↔ 英文名 ↔ 适应症 ↔ NMPA 批文号 ↔ 上市日期)精确映射。Make sure to use this skill whenever the user mentions 药品名 / 通用名 / 商品名 / NMPA / 国药准字 / 药监局 / CDE / drug brand name / generic name / drug registry / pharmaceutical lookup / drug verification / 药物核验 / 商品名对应 / drug cross-check / drug authority lookup. 在任何 medical / market-sizing / clinical / disease-research 报告生成阶段,**所有药品提及必须先调 lookup_drug() 验证**,严禁 LLM 凭训练记忆拼凑通用名↔商品名↔英文名对应关系。LLM 训练截止后药企会更换商品名、新药持续上市,记忆完全不可信。Iron Law:lookup 返回 None → 调用方必须 raise UnverifiedDrugError,不允许 fallback 到记忆。免费公开数据源,跨平台:Claude Code / Codex / Gemini CLI 三端均可 auto-trigger,实现仅依赖 httpx + beautifulsoup4 标准生态,不绑定任何厂商 SDK。
日本語の概要は準備中です。原文の説明を表示しています。
Patient safety evaluation harness for healthcare application deployments. Automated test suites for CDSS accuracy, PHI exposure, clinical workflow integrity, and integration compliance. Blocks deployments on safety failures. Use when a healthcare deployment must be gated on patient-safety tests for CDSS accuracy, PHI exposure, and workflow integrity.
日本語の概要は準備中です。原文の説明を表示しています。
Search the live web and 36+ specialised data sources including SEC filings, PubMed, ChEMBL, clinical trials, FRED economic indicators, and patent databases. Use when current, authoritative, or paywalled data is required.
日本語の概要は準備中です。原文の説明を表示しています。
Analyzes genetic variant effects on gene expression (RNA-seq), chromatin accessibility (DNASE), histone marks (ChIP), and transcription factors using the AlphaGenome API. Use when the user asks about non-coding variant effects, pathogenicity, clinical significance, disease associations, functional effects, gene expression changes, splicing disruption, or regulatory effects in promoters and enhancers. Also use for resolving biological terms to tissue/cell-type ontologies (UBERON/CL) or analyzing variants in chr:pos:ref>alt format.
日本語の概要は準備中です。原文の説明を表示しています。
Annotate and map the anatomy of any design. Identify visual hierarchy, spacing systems, color roles, and tension points through clinical analysis. Use when doing formal design audits, teaching design analysis, or building structured observation skills.
日本語の概要は準備中です。原文の説明を表示しています。
Use when user shows signs of overwhelm or frustration — repeated failed attempts, tone shifts, sudden brevity, topic abandonment. Guides gentle check-ins without being patronizing or clinical.
日本語の概要は準備中です。原文の説明を表示しています。
Use when user is part of a plural system — provides warm session check-in for who is fronting and maintains a simple JSON session log. No clinical language, no assumptions about system structure.
日本語の概要は準備中です。原文の説明を表示しています。
Statistical modeling — linear/logistic/ordinal/Poisson regression, ANOVA, Kruskal-Wallis, chi-square, Mann-Whitney, Cox survival, spline fits (R `ns()`), odds ratios, Cohen's d, F-statistic, p-value computation. Specializes in clinical-trial AE analysis (SDTM DM/AE), severity ordinal regression, and per-feature stat workflows.
日本語の概要は準備中です。原文の説明を表示しています。
Controls error rates across thousands of simultaneous tests in genomics discovery using false-discovery-rate methods (Benjamini-Hochberg 1995; Benjamini-Yekutieli 2001 for arbitrary dependence; Storey q-value with pi0 estimation; local FDR; independent filtering Bourgon 2010; covariate-weighted FDR via IHW Ignatiadis 2016), plus family-wise error control (Bonferroni, Holm) and the GWAS genome-wide threshold. Covers the FDR-versus-FWER choice as the discovery-versus-confirmatory distinction, the dependence assumptions behind BH (PRDS) versus BY, pi0 estimation, the independent-filtering and false-coverage-rate traps, and reproducibility ranking via IDR (Li 2011). Use when correcting p-values from genome-wide tests, choosing between BH/BY/q-value/Bonferroni, setting an FDR threshold, applying IHW or independent filtering, or interpreting q-values. For confirmatory trials with few pre-specified endpoints (closed testing, graphical/gatekeeping), see clinical-biostatistics/multiplicity-graphical.
日本語の概要は準備中です。原文の説明を表示しています。
Computes and interprets treatment effect measures (OR, RR, RD, HR, NNT) with calibrated confidence intervals (Wilson, Newcombe, Miettinen-Nurminen, MOVER, profile likelihood, Bender NNT) and reports marginal vs conditional estimands per FDA 2023 covariate adjustment guidance. Use when reporting treatment effects in confirmatory trials, comparing effect sizes across studies, or constructing forest plots.
日本語の概要は準備中です。原文の説明を表示しています。
Validates predictive models on omics and biomedical data with nested cross-validation, group/batch/temporal-aware splits, the full data-leakage taxonomy, probability calibration, decision-curve net benefit, optimism correction, sample-size planning, and TRIPOD+AI reporting. Use when estimating model performance honestly, choosing a CV scheme, detecting leakage, or judging whether reported discrimination means the model is actually useful. For feature selection itself see machine-learning/biomarker-discovery; for confirmatory-trial inference see clinical-biostatistics/trial-reporting.
日本語の概要は準備中です。原文の説明を表示しています。
Authors portable, strongly-typed bioinformatics pipelines in the Common Workflow Language (CWL v1.2) as CommandLineTool/Workflow/ExpressionTool documents, validated with cwltool and run at scale on Toil/Arvados/Calrissian. Use when deciding CWL (portability/provenance/regulated) vs Nextflow/WDL/Snakemake; declaring secondaryFiles for indexed companions (.bai/.fai/.dict/.tbi and the caret rule); putting resources/containers under requirements (must-hold) vs hints (advisory) to avoid silent OOM; choosing scatterMethod (dotproduct vs flat_/nested_crossproduct); preferring $(...) parameter refs over ${...} JavaScript for portability; pinning DockerRequirement images; or emitting a CWLProv provenance object for audited/clinical settings.
日本語の概要は準備中です。原文の説明を表示しています。